- Home
- PHVS vs SBGI Comparison
PHVS vs SBGI Comparison
Compare PHVS & SBGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHVS
- SBGI
- Stock Information
- Founded
- PHVS 2015
- SBGI 1986
- Country
- PHVS Switzerland
- SBGI United States
- Employees
- PHVS N/A
- SBGI N/A
- Industry
- PHVS Biotechnology: Pharmaceutical Preparations
- SBGI Broadcasting
- Sector
- PHVS Health Care
- SBGI Industrials
- Exchange
- PHVS Nasdaq
- SBGI Nasdaq
- Market Cap
- PHVS 980.9M
- SBGI 997.6M
- IPO Year
- PHVS 2021
- SBGI 1995
- Fundamental
- Price
- PHVS $22.32
- SBGI $15.09
- Analyst Decision
- PHVS Buy
- SBGI Buy
- Analyst Count
- PHVS 6
- SBGI 5
- Target Price
- PHVS $37.17
- SBGI $18.50
- AVG Volume (30 Days)
- PHVS 33.8K
- SBGI 532.7K
- Earning Date
- PHVS 08-13-2025
- SBGI 08-06-2025
- Dividend Yield
- PHVS N/A
- SBGI 6.49%
- EPS Growth
- PHVS N/A
- SBGI N/A
- EPS
- PHVS N/A
- SBGI 1.97
- Revenue
- PHVS N/A
- SBGI $3,526,000,000.00
- Revenue This Year
- PHVS N/A
- SBGI N/A
- Revenue Next Year
- PHVS N/A
- SBGI $9.59
- P/E Ratio
- PHVS N/A
- SBGI $7.67
- Revenue Growth
- PHVS N/A
- SBGI 11.62
- 52 Week Low
- PHVS $11.51
- SBGI $12.07
- 52 Week High
- PHVS $25.76
- SBGI $18.46
- Technical
- Relative Strength Index (RSI)
- PHVS 73.31
- SBGI 60.64
- Support Level
- PHVS $17.63
- SBGI $14.19
- Resistance Level
- PHVS $19.00
- SBGI $15.78
- Average True Range (ATR)
- PHVS 1.20
- SBGI 0.57
- MACD
- PHVS 0.35
- SBGI 0.22
- Stochastic Oscillator
- PHVS 92.15
- SBGI 73.66
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
About SBGI Sinclair Inc.
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their content to pay-TV distributors.